1,519
Views
8
CrossRef citations to date
0
Altmetric
Research Paper

Molecular cloning and anti-invasive activity of cathepsin L propeptide-like protein from Calotropis procera R. Br. against cancer cells

, , , , , , & show all
Pages 657-664 | Received 27 Dec 2017, Accepted 20 Feb 2018, Published online: 21 Mar 2018

References

  • Lankelma JM, Voorend DM, Barwari T, et al. Cathepsin L, target in cancer treatment? Life Sci 2010;86:225–33.
  • Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007;6:60–4.
  • Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 2015;15:712.
  • Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004;385:1017–27.
  • Kos J, Stabuc B, Schweiger A, et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 1997;3:1815–22.
  • Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543–56.
  • Ahmed A, Shamsi A, Bano B. Purification and biochemical characterization of phytocystatin from Brassica alba. J Mol Recognit 2016;29:223–31.
  • Wu J, Haard NF. Purification and characterization of a cystatin from the leaves of methyl jasmonate treated tomato plants. Comp Biochem Physiol C Toxicol Pharmacol 2000;127:209–20.
  • Li F, An H, Seymour TA, Barnes DW. Rainbow trout (Oncorhynchus mykiss) cystatin C: expression in Escherichia coli and properties of the recombinant protease inhibitor. Comp Biochem Physiol B Biochem Mol Biol 2000;125:493–502.
  • Guay J, Falgueyret JP, Ducret A, et al. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur J Biochem 2000;267:6311–8.
  • Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157–62.
  • Martínez M, Cambra I, González‐Melendi P, et al. C1A cysteine-proteases and their inhibitors in plants. Physiol Plant 2012;145:85–94.
  • Ramos M, Araújo E, Jucá T, et al. New insights into the complex mixture of latex cysteine peptidases in Calotropis procera. Int J Biol Macromol 2013;58:211–19.
  • Kumar Dubey V, Jagannadham M. Procerain, a stable cysteine protease from the latex of Calotropis procera. Phytochemistry 2003;62:1057–71.
  • Singh AN, Shukla AK, Jagannadham M, Dubey VK. Purification of a novel cysteine protease, procerain B, from Calotropis procera with distinct characteristics compared to procerain. Process Biochem 2010;45:399–406.
  • Singh AN, Yadav P, Dubey VK. cDNA cloning and molecular modeling of Procerain B, a novel cysteine endopeptidase isolated from Calotropis procera. PLoS One 2013;8:e59806.
  • Kwon CW, Park KM, Kang BC, et al. Cysteine protease profiles of the medicinal plant Calotropis procera R. Br. revealed by de novo transcriptome analysis. PloS One 2015;10:e0119328.
  • Barrett AJ, Kembhavi A, Brown M, et al. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 1982;201:189–98.
  • Cha S. Tight-binding inhibitors-I. Kinetic behavior. Biochem Pharmacol 1975;24:2177–85.
  • Izquierdo-Martin M, Stein RL. Mechanistic studies on the inhibition of thermolysin by a peptide hydroxamic acid. J Am Chem Soc 1992;114:325–31.
  • Wiederanders B, Kaulmann G, Schilling K. Functions of propeptide parts in cysteine proteases. Curr Protein Pept Sci 2003;4:309–26.
  • Kurata M, Yamamoto Y, Watabe S, et al. Bombyx cysteine proteinase inhibitor (BCPI) homologous to propeptide regions of cysteine proteinases is a strong, selective inhibitor of cathepsin L-like cysteine proteinases. J Biochem 2001;130:857–63.
  • Deshapriya RM, Takeuchi A, Shirao K, et al. Drosophila CTLA-2-like protein (D/CTLA-2) inhibits cysteine proteinase 1 (CP1), a cathepsin L-like enzyme. Zoolog Sci 2007;24:21–30.
  • Delaria K, Fiorentino L, Wallace L, et al. Inhibition of cathepsin L-like cysteine proteases by cytotoxic T-lymphocyte antigen-2 beta. J Biol Chem 1994;269:25172–7.
  • Chowdhury SF, Sivaraman J, Wang J, et al. Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides. J Med Chem 2002;45:5321–9.